PDUFA Provisions Could Harm FDA and Industry, Expert Says

PDUFA Provisions Could Harm FDA and Industry, Expert Says

By Peter Pitts
August 27,2007

Drug Industry Daily

Some of the provisions in the FDA Revitalization Act, S. 1082 and H.R. 2900, will be ineffective and could cripple the FDA and put unnecessary burdens on pharmaceutical companies, Center
for Medicines in the Public Interest President Peter Pitts said. “Political battles are trumping public health,” he added, at the Third Annual FDA Regulatory and Compliance Symposium at
Harvard University.

Featured

Animal health and human health are inextricably linked
  May 15, 2012  
Drug Shortages and the Role of the Middle Man
 April 13, 2012  
Obamacare's Medical Mercenaries
 April 13, 2012  

Social Networks

Receive latest news & event updates
Provide email below:

Like CMPI on Facebook
Follow CMPI on Twitter
Connect with CMPI on LinkedIn
Watch our Videos on CMPI YouTube Channel
Subscribe to Receive CMPI RSS Feeds